Endocrine News Podcast

Endocrine News Podcast

by Endocrine Society
Season 2023

ENP76: Infants and In Utero Exposure to COVID

ENP75: A Case Study on Fungal Sinusitis in T2D

From ENDO 2023, host Aaron Lohr talks with Jayalakshmi Udayasankar, MD, from the Palo Alto Medical Foundation, about her team’s research presented at the meeting, titled, “Tingling Over Cheek: An Atypical Presentation of Invasive Fungal Sinusitis in an Ambulatory Patient With Type 2 Diabetes.” Show notes are available at https://www.endocrine.org/podcast/enp75-a-case-study-on-fungal-sinusitis-in-t2d — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ENP74: Healthy and Unhealthy Obesity

In another dispatch from ENDO 2023, host Aaron Lohr talks with Max Petersen, MD, PhD, from Washington University in St. Louis, about his team’s research presented at the meeting. Their presentation was titled, “Cellular Insights Into Metabolically Healthy and Unhealthy Obesity.” Show notes are available at https://www.endocrine.org/podcast/enp74-healthy-and-unhealthy-obesity — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ENP73: A Robotic Teriparatide Pill to Treat Osteoporosis

Host Aaron Lohr talks with two researchers at ENDO 2023, Kyle Horlen, DVM, and Joshua Myers, both from Rani Therapeutics, about two presentations they made about an oral treatment of teriparatide for the treatment of osteoporosis. The two presentations are titled, “Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Parathyroid Hormone Analog PTH (1-34) (Teriparatide) Delivered via an Orally Administered Robotic Pill (RT-102),” and “An Orally Administered Robotic Pill (RP) Reliably And Safely Delivers the Human Parathyroid Hormone Analog hPTH(1-34) (Teriparatide) With High Bioavailability in Healthy Human Volunteers: A Phase 1 Study.” Show notes are available at https://www.endocrine.org/podcast/enp73-a-robotic-teriparatide-pill-to-treat-osteoporosis — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ENP72: GHR, Insulin, and Life Span

In another interview from ENDO 2023, host Aaron Lohr talks with Silvana Duran Ortiz, Ph.D., a postdoctoral research fellow at Ohio University, about her team’s research presented at the meeting. Their presentation was titled, “Disruption of GHR in ‘Middle Aged’ Mice Enhances Insulin Sensitivity and Extends Male Lifespan.” Show notes are available at https://www.endocrine.org/podcast/enp72-ghr-insulin-and-life-span — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ENP71: Lactation and Maternal Metabolism

ENP70: Hormones and Aging

Whether we like it or not, we’re all getting older. What do we know about how aging impacts our endocrine system? What don’t we know? That’s what we’re here to talk about today, as we look at the new scientific statement from the Endocrine Society titled, “Hormones and Aging: An Endocrine Society Scientific Statement.” Host Aaron Lohr talks with one of the statement’s authors, Anne Cappola, MD, a professor of medicine at the University of Pennsylvania and founding director of Penn Medical Communication Research Institute. Show notes are available at https://www.endocrine.org/podcast/enp70-hormones-and-aging — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ENP69: Biosimilar Insulin

In this episode, we hear about biosimilar insulin: its safety, efficacy, what sets it apart from biologic insulin, and when it should be considered for use. Host Aaron Lohr talks with Irl Hirsch, MD, professor of medicine at the University of Washington Medicine Diabetes Institute. This episode is made possible through an unrestricted, educational grant from Viatris. Show notes are available at https://www.endocrine.org/podcast/enp69-biosimilar-insulin — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ENP68: Hypercalcemia of Malignancy

Recently the Endocrine Society published a new clinical practice guideline entitled, “Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline.” What exactly is hypercalcemia of malignancy? What are its symptoms? How is it treated? And what do the guidelines recommend? To help answer these questions, host Aaron Lohr talks with Ghada El-Hajj Fuleihan, MD, MPH, professor of medicine at the American University in Beirut in Lebanon. She is the chair of the Society working group that developed this guideline. Show notes are available at https://www.endocrine.org/podcast/enp68-hypercalcemia-of-malignancy — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

ENP67: Growth Hormone Deficiency

In this episode, host Aaron Lohr discusses screening, diagnosis, and current and emerging treatment options for the long-term management of growth hormone deficiency in pediatric and adult patients with Dr. Mark E. Molitch, MD, Professor Emeritus of Medicine, Northwestern University Feinberg School of Medicine. In addition, Dr. Molitch gives listeners a four-question quiz at the end. Remember to pause in between the question and answer! This episode is certified for up to 0.5 American Medical Association Physician’s Recognition Award (AMA PRA) Category 1 credits and American Board of Internal Medicine Maintenance of Certification (ABIM MOC) points. This episode is made possible by an unrestricted, educational grant from Novo Nordisk. Show notes are available at https://www.endocrine.org/podcast/enp67-growth-hormone-deficiency — for helpful links, including to the AMA PRA exam, or to hear more podcast episodes, visit https://www.endocrine.org/podcast
5 of 12